rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SLDB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
      Nov 17Yahoo FinanceSLDB
      Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
      Nov 10Yahoo FinanceSLDB
      Solid Biosciences a new Outperform at William Blair on Duchenne asset
      Nov 9Seeking AlphaSLDB
      Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 5Yahoo FinanceSLDB
      Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
      Nov 4Yahoo FinanceSLDB
      H.C. Wainwright reiterates Solid Biosciences stock rating on EU designation
      Oct 27Investing.comSLDB
      Solid Biosciences receives EU orphan designation for SGT-212
      Oct 26Investing.comSLDB
      Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
      Oct 26Yahoo FinanceSLDB
      Leerink Partners Remains a Buy on Solid Biosciences (SLDB)

      Tipranks Press Release.

      Oct 21The Globe and MailSLDB
      Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
      Oct 20Yahoo FinanceSLDB
      UBS Initiates Solid Biosciences at Buy With $20 Price Target
      Oct 15Yahoo FinanceSLDB
      Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable

      Oct 1Yahoo FinanceSLDB
      Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)

      Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailSLDB
      Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)

      Solid Biosciences is leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. Learn more about SLDB stock here.

      Sep 25Seeking AlphaSLDB
      Exclusive BAC Article: Solid Biosciences; FDA Meeting Q4 2026 For Potential AA Filing SGT-003 For DMD, Two Other Gene Therapy Readouts 1st Half 2027, Capsid Differentiation SGT-003, And Catalysts (NASDAQ:SLDB)
      Sep 16Seeking AlphaSLDB
      Solid Biosciences wins new Outperform at RBC on DMD opportunity
      Sep 16Seeking AlphaSLDB
      Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

      Solid Biosciences' (SLDB) differentiated approach to Duchenne muscular dystrophy and a "materially d

      Sep 16Yahoo FinanceSLDB
      Cantor Fitzgerald reiterates Overweight on Solid Biosciences stock
      Sep 16Investing.comSLDB
      RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target

      Solid Biosciences (SLDB) has an average rating of buy and mean price target of $18.62, according to

      Sep 16Yahoo FinanceSLDB
      Solid Biosciences at H.C. Wainwright conference: FDA milestones loom
      Sep 14Investing.comSLDB
      H.C. Wainwright reiterates Solid Biosciences stock rating at buy
      Sep 14Investing.comSLDB
      Solid Biosciences at Citi summit: FDA tests loom for gene therapy push
      Sep 10Investing.comSLDB
      Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push
      Sep 9Investing.comSLDB
      Solid Biosciences to Participate at Upcoming Investor Conferences

      CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare ConferenceBo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A li

      Sep 2Yahoo FinanceSLDB
      Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

      Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailNEOSLDB
      Cantor raises Solid Biosciences stock price target on gene therapy
      Aug 27Investing.comSLDB

      This is the newest page. Registered accounts read further back.